α-干扰素联合恩替卡韦治疗慢性乙型肝炎患者疗效研究

doi:10.3969/j.issn.1672-5069.2017.04.028

Abstract

Shi Hanyan, Xu Xiaorong.. Peg-interferon-α2a and entecavir in treatment of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 488-489.

[1] 康海燕,王琳,李铁牛,等. 聚乙二醇干扰素在老年e抗原阴性慢性乙型肝炎治疗中的疗效. 中国老年学杂志,2016,6（1）:191-192.
[2] Teschke R,Danan G. Drug-induced liver injury:Is chronic liver disease a risk factor and a clinical issue. Expert Opin Drug Metab Toxicol,2016,45（3）:1-14.
[3] 靳丽,李明慧,张丹,等. 慢性乙型肝炎治疗前X区变异与聚乙二醇干扰素α-2a治疗疗效的关系研究.中华实验和临床病毒学杂志,2016,30（4）:389-392.
[4] 张夏华,吴广通,米丽,等. 慢性乙型肝炎治疗中影响HBeAg转阴和定量的有关因素分析. 胃肠病学杂志,2013,18（11）:683-685.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[6] 王灵台.关于慢性乙型肝炎治疗的几点新认识.传染病信息,2012,25（3）:132-134.
[7] 刘树人,欧阳石,陈汉先,等. 慢性乙型肝炎治疗达标停药后复发与HBV-DNA载量关系.中华实用诊断与治疗杂志,2013,27（7）:663-664,667.
[8] Liang LB,Zhu X,Yan LB,et al. Quantitative intrahepatic HBV cccDNA correlates with histological liver inflammation in chronic hepatitis B virus infection. Int Infect Dis,2016,52（7）:77-82.
[9] 官亮,邓欢,龚辉,等. 恩替卡韦联合胸腺肽对HBeAg阴性慢性乙型肝炎患者病毒动力学的影响.中国老年学杂志,2014,45（23）:6791-6792.
[10] Liu F,Duan X,Wan Z,et al. Lower number and decreased function of natural killer cells in hepatitis B virus related acute-on-chronic liver failure. Clin Res Hepatol Gastroenterol, 2016,40（5）:605-613.
[11] 蔺咏梅,杨雪亮,叶峰,等. 恩替卡韦对HBeAg阳性慢性乙型肝炎患者的免疫调节作用. 西安交通大学学报（医学版）,2014,35（5）:655-658,689.
[12] 聂尚燕,宋欢欢,王敏,等. 干扰素α2b联合拉米夫定治疗慢性乙型肝炎患者血清HBeAg阴转和肝功能的变化.实用肝脏病杂志,2016,13（1）:86-87.
[13] Sun M,Tan G,Song J,et al. Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol,2016,40（5）:590-596.
[14] 肖寒,马陈斌,张利霞,等. 恩替卡韦对慢性乙型肝炎患者血清中HBV DNA载量与TGF-β1的影响. 南方医科大学学报,2012,32（4）:589-592.
[15] 伦秀英. 血清HBeAg定量变化与慢性乙型肝炎治疗应答的相关性研究. 中华实验和临床病毒学杂志,2012,26（4）:295-297.
[16] Karacaer Z,Cakir B,Erdem H,et al. Quality of life and related factors among chronic hepatitis B-infected patients:a multi-center study,Turkey. Health Qual Life Outcomes,2016,14（1）:153.
[17] 马宏,黄祎诺,魏书堂,等. 胸腺肽α1在慢性乙型肝炎治疗中的研究进展. 医学综述,2016,22（10）:1895-1899.
[18] 肖素芬,舒永水,张光荣,等. 干扰素辅助治疗对慢性乙型肝炎患者血清TH1/TH2及IL-12水平影响研究.中国生化药物杂志,2015,34（11）:83-85.
[19] Ormeci A,Aydin Y,Sumnu A,et al. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels. Int Infect Dis,2016,52（6）:68-73.
[20] 温焕连,杨海红,曾文铤,等. 恩替卡韦对不同性别慢性乙型肝炎患者的疗效比较. 广东医学,2015,26（3）:457-459.
[21] 李媚,唐保东,杨琛,等. α-干扰素联合恩替卡韦治疗慢性乙型肝炎患者疗效Meta分析. 实用肝脏病杂志,2014,36（6）:583-587.

Peg-interferon-α2a and entecavir in treatment of patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[7]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[8]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[9]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[10]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[11]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[12]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[13]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[14]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[15]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.